ACE Inhibitor Therapy

Primary Indications

The American Heart Association recommends ACE inhibitors for all patients with heart failure with reduced ejection fraction (HFrEF) with current or prior symptoms to reduce mortality and hospitalization, unless contraindicated 1, 2
The American Diabetes Association suggests that ACE inhibitors are particularly beneficial in patients with type 1 diabetic nephropathy and may be beneficial in type 2 diabetic nephropathy 3, 4

The American College of Cardiology recommends ACE inhibitors as preferred agents for patients with diabetes to achieve target blood pressure <130/80 mmHg, offering renoprotective effects beyond blood pressure control 3
The European Society of Cardiology strongly indicates ACE inhibitors for patients with left ventricular dysfunction with or without symptomatic heart failure 4, 5

The American Heart Association suggests that treatment should be initiated at low doses and gradually increased if tolerated 1, 2
Common ACE inhibitors and their dosing ranges include:
- Captopril: Initial 6.25 mg three times daily, maximum 50 mg three times daily 2, 5
- Enalapril: Initial 2.5 mg twice daily, maximum 10-20 mg twice daily 2, 5
- Lisinopril: Initial 2.5-5 mg once daily, maximum 20-40 mg once daily 2, 5
- Ramipril: Initial 1.25-2.5 mg once daily, maximum 10 mg once daily 2, 5

The American College of Cardiology recommends that renal function and serum potassium should be assessed within 1-2 weeks of initiation and periodically thereafter 1, 2
More frequent monitoring is needed in patients with preexisting hypotension, hyponatremia, diabetes mellitus, azotemia, or those taking potassium supplements 1, 2

The American Heart Association states that absolute contraindications for ACE inhibitors include history of angioedema with previous ACE inhibitor use, pregnancy or planning pregnancy, and bilateral renal artery stenosis 1, 5
The European Society of Cardiology recommends using ACE inhibitors with caution in patients with very low systemic blood pressure, markedly increased serum creatinine, elevated serum potassium, or peripheral vascular disease due to association with renovascular disease 1, 2, 4, 6

The American College of Cardiology recommends angiotensin receptor blockers (ARBs) as alternatives for patients who cannot tolerate ACE inhibitors due to cough or angioedema 5

The American Heart Association notes that dry, persistent cough occurs in up to 20% of patients and is a common reason for discontinuation 8
The American College of Cardiology states that angioedema is rare (<1%) but potentially life-threatening, and more common in Black patients 8
The European Society of Cardiology recommends monitoring potassium levels, especially when combined with potassium-sparing diuretics, to prevent hyperkalemia 1, 2

The American College of Cardiology suggests that abrupt withdrawal of ACE inhibitors should be avoided as it can lead to clinical deterioration in heart failure patients 1, 2
The American Heart Association recommends that when target doses cannot be achieved due to intolerance, intermediate doses should be used, as there are likely only small differences in efficacy between low and high doses 1, 2
The European Society of Cardiology states that in patients with heart failure, ACE inhibitors should be used together with a beta-blocker unless contraindicated 1, 2